Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 17/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 17/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1194108 | 0.88 | PIK3CD (0.52) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2688815 | 0.87 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1309323 | 0.87 | PIK3CD (0.60) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1193909 | 0.86 | PIK3CD (0.60) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL994932 | 0.85 | PIK3CD (0.74) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1194162 | 0.85 | PIK3CD (0.75) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1195224 | 0.85 | PIK3CD (0.58) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1309524 | 0.85 | PIK3CD (0.75) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL10330134 | 0.81 | PIK3CA (0.38) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL13982550 | 0.79 | ATR (0.59) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | claimed |
| WO-2012009452-A1 | THE ROLE OF P13K P110 DELTA SIGNALING IN RETROVIRAL INFECTION AND REPLICATION | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-01-19 | — | — | WO | claimed |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-09 | — | — | US | disclosed |
| US-20120184519-A1 | Compositions and Methods for Preventing or Treating Influenza Virus Infection | THE BABRAHAM INSTITUTE | 2012-07-19 | — | — | US | disclosed |
| US-20110135655-A1 | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication | PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135655-A1 | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication | PIK3R5, PIK3R4, PIK3R1 | PIK3CD 5/4885PIK3CA 10/4885PIK3CB 11/4885 |
| US-20120184519-A1 | Compositions and Methods for Preventing or Treating Influenza Virus Infection | PIK3R5, PIK3C2A, PIK3C2B | PIK3CD 6/4885PIK3CA 9/4885PIK3CB 10/4885 |
| US-20130116267-A1 | Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication | PIK3R5, PIK3R4, PIK3R3 | PIK3CD 6/4885PIK3CA 10/4885PIK3CB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.